DrStockPick.com Stock Report!
Monday August 17, 2009
Linktone Ltd. (Nasdaq: LTON), one of the leading providers of wireless interactive entertainment services to consumers in China, today announced that it will report financial results for the second quarter ended June 30, 2009, after the U.S. equities markets close on Tuesday, August 25, 2009.
China-Biotics, Inc. (Nasdaq: CHBT), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced its financial results for the first quarter of its 2010 fiscal year, ended June 30, 2009.
Cognizant (Nasdaq: CTSH), a leading provider of consulting, technology, and business process outsourcing (BPO) services, has announced the operational expansion of its Phoenix delivery center, adding BPO services to an existing roster of application development, application maintenance, testing, and related services.
Vasogen Inc. (NASDAQ:VSGN) and IntelliPharmaCeutics (IPC) announced today that they have entered into a definitive agreement, subject to shareholder and regulatory approvals, whereby Vasogen will combine with IPC under a plan of arrangement and merger to continue as a publicly-traded entity to be called IntelliPharmaCeutics International Ltd. IPC is a privately-held specialty pharmaceutical company that is focused on developing and manufacturing new and generic controlled-release pharmaceutical products using its broadly applicable, proprietary delivery technologies. Currently, IPC has 15 product candidates in its development pipeline several of which are partnered with third-party drug companies. IPC’s lead product candidates include Dexmethylphenidate XR, a generic version of the marketed drug Focalin XR(R), which is partnered with Par Pharmaceutical and is currently the subject of an Abbreviated New Drug Application (ANDA) filing with the U.S. Food and Drug Administration (FDA), and Carvedilol CR, a generic version of the brand name drug Coreg CR, an internal pipeline product now ready for entry into pivotal bioequivalence studies.
R.R. Donnelley & Sons Company (NASDAQ: RRD) announced today that it has expanded its European service capabilities with the opening of a new facility in Debrecen, in Eastern Hungary.
ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the appointment of Peter Williams as Vice President, Business Development.
Source: E-Gate System from Alphatrade.com
No comments:
Post a Comment